• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Digital Health Fundings Seem to be Cooling Off After a Blazing Hot Q3

Share:

December 1, 2020

A Q4 progress report from CB Insights predicts a drop-off in investment between the quarters, for digital health and the broader healthcare startup ecosystem alike.

Digital health funding in the final quarter of 2020 may not reach the staggering heights of the preceding quarter, but the final few weeks of raises are still projected to edge out the investments of Q4 2019, according to a report from CB Insights.

WHAT’S THE IMPACT

Based on equity financing reported through Nov. 17, the industry analyst’s preview report pegs worldwide digital health fundings to land at 372 deals totaling roughly $5.54 billion by the end of the fourth quarter. This would fall substantially lower than the 505 deals and $8.44 billion CB Insights logged for Q3, but still a hair higher than the $4.96 billion (from 457 deals) in Q4 2019.

While the drop from Q3 to Q4 is substantial for digital health, the decline is lessened (but still present) across the broader healthcare funding landscape. Per the report’s projections, global healthcare funding is expected to decline from $22.35 billion to $19.58 billion between the quarters. CB Insights also highlighted a potential shift in the types of deals being cut, with fewer angel, seed, Series A and convertible note rounds anticipated in Q4 than during any quarter prior.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“At the current pace, funding and deal activity in both global healthcare and digital health are projected to decline from the previous quarter’s record highs,” CB Insights wrote in the preview report. “As we saw in Q3’20, late-stage deals continue to make up a larger deal share than it had in previous quarters. Simultaneously, early-stage deals currently have a lower proportion of total equity deals at 46% compared to the 51% we saw Q3’20.”

THE LARGER TREND

Funding for digital health startups has been on a breakneck pace throughout 2020, but the third quarter in particular was an unprecedented standout for those seeking new funds in COVID-19-impacted sectors of the industry such as on-demand healthcare services or digital-enabled fitness platforms. However, CB Insights’ latest report suggests that digital health investors are backing down a bit from the Q3 frenzy.

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • ICU Medical, Inc. to Acquire Pursuit Vascular, Inc.ICU Medical, Inc. to Acquire Pursuit Vascular, Inc.
  • Blockchain Hype May Finally Turn Into Reality in PharmaceuticalsBlockchain Hype May Finally Turn Into Reality in Pharmaceuticals
  • Danaher to Acquire the Biopharma Business of General Electric Life Sciences for $21.4 BillionDanaher to Acquire the Biopharma Business of General Electric Life Sciences for $21.4 Billion
  • Amwell Raises $194M to Expand Telehealth Platform to Combat COVID-19 PandemicAmwell Raises $194M to Expand Telehealth Platform to Combat COVID-19 Pandemic
  • Blade Therapeutics Eyes Nasdaq in 2022 with Planned SPAC MergerBlade Therapeutics Eyes Nasdaq in 2022 with Planned SPAC Merger
  • Kyocera to Purchase Major Assets of U.S.-based Renovis Surgical Technologies, Inc.Kyocera to Purchase Major Assets of U.S.-based Renovis Surgical Technologies, Inc.
  • Rogers, Shaw tick lower amid a report that Industry Minister in no hurry to Ok dealRogers, Shaw tick lower amid a report that Industry Minister in no hurry to Ok deal
  • Roche and Sarepta Partner on Duchenne Muscular Dystrophy TherapyRoche and Sarepta Partner on Duchenne Muscular Dystrophy Therapy

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications